コレラワクチンの市場：タイプ、投与方法、エンドユーザー、年齢層別-2025-2030年の世界予測

コレラワクチン市場は、2023年に2億8,642万米ドルと評価され、2024年には3億702万米ドルに達すると予測され、CAGR 7.32%で成長し、2030年には4億6,983万米ドルに達すると予測されています。

コレラワクチンは、コレラの流行地域全体でコレラ発生の影響を緩和する上で重要な役割を果たしています。ワクチン市場には、Dukoral、Shanchol、Euvicholなどの経口ワクチンが含まれ、主に発展途上国、旅行者、アウトブレイクが発生している地域のハイリスク集団を対象としています。清潔な水や衛生設備へのアクセスが限られているため、胆汁性疾患の流行が続いていることが、こうしたワクチンの必要性を高めています。ワクチンの用途は主に、流行時の予防接種と高リスク地域での定期投与に及び、最終用途は公衆衛生機関、NGO、国際的な予防接種プログラムなど多岐にわたる。市場の成長は、認知度の向上、政府のイニシアティブ、国際的な資金調達、新たなワクチン技術によって推進されています。最近では、費用対効果が高く、より長持ちするワクチンが開発される可能性があり、メーカーが保健機関と提携して流通網を拡大する機会も生まれています。とはいえ、ロジスティクスの課題、コールドチェーンの制約、過疎地における認知度の低さなどが限界であり、市場拡大の大きな障壁となっています。さらに、特定の国における政情不安や規制当局の承認が、一貫した市場成長の課題となる可能性もあります。成長機会を活用するために、企業は耐熱性製剤、免疫原性の向上、物流負担を軽減するための単回投与レジメンなどの分野で技術革新を行うべきです。遺伝子組み換え経口ワクチンの研究やコレラのmRNAプラットフォームの探求は、予防戦略を一変させる可能性があります。市場浸透には、多様で手頃な価格の製品ポートフォリオと公衆衛生機関との戦略的協力関係が必要です。市場は依然としてダイナミックで、定期的に発生するアウトブレイクによって需要が急増するため、事業者はこうした変動に機敏に対応する必要があります。地域の疾病負担とアンメットニーズを理解することで、市場参入を成功に導き、現在の課題にもかかわらず持続的な成長を確保することができます。

市場力学：急速に進化するコレラワクチン市場の主要市場インサイトを公開

コレラワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のコレラ患者数の増加
  • コレラ予防接種のための政府による支援キャンペーン
• 市場抑制要因
  • ワクチン開発コストの高さと製品不足の問題
• 市場機会
  • 組換えDNA技術と細胞ベースの生産システムの開発
  • コレラワクチンの包装および保管ソリューションの革新
• 市場の課題
  • 熟練したヘルスケア専門家の世界の不足

ポーターのファイブフォース：コレラワクチン市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：コレラワクチン市場における外部からの影響の把握

外部マクロ環境要因は、コレラワクチン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析コレラワクチン市場における競合情勢の把握

コレラワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスコレラワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、コレラワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨コレラワクチン市場における成功への道筋を描く

コレラワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でコレラ感染者数が増加
    • コレラ予防接種に対する政府の支援的な宣伝キャンペーン
  • 抑制要因
    • ワクチン開発の高コストと製品不足の問題
  • 機会
    • 組み換えDNA技術と細胞ベースの生産システムの発展
    • コレラワクチンのパッケージングと保管ソリューションの革新
  • 課題
    • 世界中で熟練したヘルスケア専門家の不足
• 市場セグメンテーション分析
  • タイプ：強力な免疫反応を刺激する能力があるため、弱毒化ワクチンの採用率が高い
  • エンドユーザー：コレラ予防法と予防接種の重要性について人々を教育することに重点を置いた政府の予防接種プログラムの重要性が高まっています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 コレラワクチンの市場：タイプ別

• 不活化ワクチン
• 生弱毒化ワクチン

第7章 コレラワクチンの市場投与方法別

• 注射ワクチン
• 経口ワクチン

第8章 コレラワクチンの市場：エンドユーザー別

• 政府のワクチン接種プログラム
• 病院・クリニック

第9章 コレラワクチンの市場：年齢層別

• 大人
• 子供たち

第10章 南北アメリカのコレラワクチンの市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のコレラワクチンの市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのコレラワクチンの市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • コレラワクチン接種における戦略的技術移転：IVIとBiological E. Limitedの提携
  • GCバイオファーマとユービオロジクスによるコレラワクチン生産に関する戦略的提携
  • TechInvention、Eubiologicsとの提携によりインドで革新的なコレラワクチンパッケージを導入
• 戦略分析と提言

企業一覧

• Astellas Pharma Inc.
• Beijing Minhai Biological Technology Co., Ltd.
• Bharat Biotech Ltd.
• Bio-Manguinhos
• Biological E Ltd
• BioVac by Ceva Sante Animale
• Emergent BioSolutions Inc.
• GlaxoSmithKline plc
• Haffkine Bio-Pharmaceutical Corporation Ltd
• Incepta Pharmaceuticals Ltd.
• Merck & Co. Inc
• Panacea Biotec Ltd
• Sanofi S.A.
• SK Inc.
• Techinvention Lifecare Pvt. Ltd.
• Valneva SE

LIST OF FIGURES

• FIGURE 1. CHOLERA VACCINES MARKET RESEARCH PROCESS
• FIGURE 2. CHOLERA VACCINES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CHOLERA VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CHOLERA VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CHOLERA VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CHOLERA VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CHOLERA VACCINES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CHOLERA VACCINES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CHOLERA VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CHOLERA VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CHOLERA VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CHOLERA VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CHOLERA VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CHOLERA VACCINES MARKET DYNAMICS
• TABLE 7. GLOBAL CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INJECTABLE VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GOVERNMENT VACCINATION PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CHOLERA VACCINES MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 32. CANADA CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. CANADA CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. CANADA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. CANADA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 54. CHINA CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. CHINA CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. CHINA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. CHINA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 58. INDIA CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. INDIA CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. INDIA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. INDIA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 62. INDONESIA CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. INDONESIA CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 66. JAPAN CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. JAPAN CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 70. MALAYSIA CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. MALAYSIA CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 74. PHILIPPINES CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. PHILIPPINES CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 78. SINGAPORE CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. SINGAPORE CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 82. SOUTH KOREA CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. SOUTH KOREA CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 86. TAIWAN CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. TAIWAN CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 90. THAILAND CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. THAILAND CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 94. VIETNAM CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. VIETNAM CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 98. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 103. DENMARK CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. DENMARK CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 107. EGYPT CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. EGYPT CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 111. FINLAND CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. FINLAND CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 115. FRANCE CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. FRANCE CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 119. GERMANY CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. GERMANY CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 123. ISRAEL CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. ISRAEL CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 127. ITALY CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. ITALY CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. ITALY CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. ITALY CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 131. NETHERLANDS CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. NETHERLANDS CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 135. NIGERIA CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. NIGERIA CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 139. NORWAY CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. NORWAY CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 143. POLAND CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. POLAND CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. POLAND CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. POLAND CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 147. QATAR CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. QATAR CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. QATAR CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. QATAR CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 151. RUSSIA CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 152. RUSSIA CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 155. SAUDI ARABIA CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. SAUDI ARABIA CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 159. SOUTH AFRICA CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SOUTH AFRICA CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 163. SPAIN CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SPAIN CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 167. SWEDEN CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SWEDEN CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 171. SWITZERLAND CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SWITZERLAND CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 175. TURKEY CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 176. TURKEY CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 179. UNITED ARAB EMIRATES CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 180. UNITED ARAB EMIRATES CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 183. UNITED KINGDOM CHOLERA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED KINGDOM CHOLERA VACCINES MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 187. CHOLERA VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 188. CHOLERA VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

The Cholera Vaccines Market was valued at USD 286.42 million in 2023, expected to reach USD 307.02 million in 2024, and is projected to grow at a CAGR of 7.32%, to USD 469.83 million by 2030.

Cholera vaccines play a critical role in mitigating the impact of cholera outbreaks across endemic regions. The vaccine market encompasses oral vaccines such as Dukoral, Shanchol, and Euvichol, primarily targeting high-risk populations in developing countries, travelers, and regions experiencing outbreaks. There's a rising necessity for these vaccines driven by persistent choleral outbreaks due to limited access to clean water and sanitation. The application of vaccines mainly spans prophylactic immunization during epidemics and routine administration in high-risk areas, with end-use across public health agencies, NGOs, and international vaccination programs. Market growth is propelled by increased awareness, government initiatives, international funding, and emerging vaccine technologies. Recently, there is potential for cost-effective, longer-lasting vaccines, fostering opportunities for manufacturers to partner with health organizations to expand distribution networks. Nevertheless, limitations include logistical challenges, cold chain constraints, and a lack of awareness in underdeveloped areas which pose as significant barriers to market expansion. Additionally, political instability and regulatory approvals in certain countries can challenge consistent market growth. To capitalize on growth opportunities, businesses should innovate in fields like thermostable formulations, enhanced immunogenicity, and single-dose regimens to reduce logistical burdens. Research into genetically engineered oral vaccines and exploring the mRNA platform for cholera could transform prevention strategies. A diverse, affordable product portfolio and strategic collaborations with public health agencies are necessary for market penetration. The market remains dynamic with periodic demand spikes driven by outbreaks, and operators must stay agile to respond to these fluctuations. Understanding regional disease burden and unmet needs can guide successful market entries and ensure sustainable growth despite current challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cholera Vaccines Market

The Cholera Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising number of cholera cases across the globe
  • Supportive government promotional campaigns for cholera vaccination
• Market Restraints
  • High cost of vaccine development coupled with issues of product shortages
• Market Opportunities
  • Developments in recombinant DNA technology and cell-based production systems
  • Innovations in packaging and storage solutions for cholera vaccines
• Market Challenges
  • Limited availability of skilled healthcare professionals worldwide

Porter's Five Forces: A Strategic Tool for Navigating the Cholera Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cholera Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cholera Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cholera Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cholera Vaccines Market

A detailed market share analysis in the Cholera Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cholera Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cholera Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cholera Vaccines Market

A strategic analysis of the Cholera Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cholera Vaccines Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., Beijing Minhai Biological Technology Co., Ltd., Bharat Biotech Ltd., Bio-Manguinhos, Biological E Ltd, BioVac by Ceva Sante Animale, Emergent BioSolutions Inc., GlaxoSmithKline plc, Haffkine Bio-Pharmaceutical Corporation Ltd, Incepta Pharmaceuticals Ltd., Merck & Co. Inc, Panacea Biotec Ltd, Sanofi S.A., SK Inc., Techinvention Lifecare Pvt. Ltd., and Valneva SE.

Market Segmentation & Coverage

This research report categorizes the Cholera Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Inactivated Vaccine and Live Attenuated Vaccine.
• Based on Method of Administration, market is studied across Injectable Vaccines and Oral Vaccines.
• Based on End User, market is studied across Government Vaccination Programs and Hospitals & Clinics.
• Based on Age Group, market is studied across Adults and Children.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising number of cholera cases across the globe
    • 5.1.1.2. Supportive government promotional campaigns for cholera vaccination
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of vaccine development coupled with issues of product shortages
  • 5.1.3. Opportunities
    • 5.1.3.1. Developments in recombinant DNA technology and cell-based production systems
    • 5.1.3.2. Innovations in packaging and storage solutions for cholera vaccines
  • 5.1.4. Challenges
    • 5.1.4.1. Limited availability of skilled healthcare professionals worldwide
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Higher adoption of attenuated vaccines owing to their ability to stimulate strong immune responses
  • 5.2.2. End User: Growing significance of Government vaccination programs, focusing on educating people about cholera prevention methods and the importance of vaccination
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cholera Vaccines Market, by Type

• 6.1. Introduction
• 6.2. Inactivated Vaccine
• 6.3. Live Attenuated Vaccine

7. Cholera Vaccines Market, by Method of Administration

• 7.1. Introduction
• 7.2. Injectable Vaccines
• 7.3. Oral Vaccines

8. Cholera Vaccines Market, by End User

• 8.1. Introduction
• 8.2. Government Vaccination Programs
• 8.3. Hospitals & Clinics

9. Cholera Vaccines Market, by Age Group

• 9.1. Introduction
• 9.2. Adults
• 9.3. Children

10. Americas Cholera Vaccines Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cholera Vaccines Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cholera Vaccines Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Strategic Technology Transfer in Cholera Vaccination: A Partnership Between IVI and Biological E. Limited
  • 13.3.2. Strategic Collaboration for Cholera Vaccine Production between GC Biopharma and Eubiologics
  • 13.3.3. TechInvention Introduces Innovative Cholera Vaccine Packaging in India with Eubiologics Partnership
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Astellas Pharma Inc.
• 2. Beijing Minhai Biological Technology Co., Ltd.
• 3. Bharat Biotech Ltd.
• 4. Bio-Manguinhos
• 5. Biological E Ltd
• 6. BioVac by Ceva Sante Animale
• 7. Emergent BioSolutions Inc.
• 8. GlaxoSmithKline plc
• 9. Haffkine Bio-Pharmaceutical Corporation Ltd
• 10. Incepta Pharmaceuticals Ltd.
• 11. Merck & Co. Inc
• 12. Panacea Biotec Ltd
• 13. Sanofi S.A.
• 14. SK Inc.
• 15. Techinvention Lifecare Pvt. Ltd.
• 16. Valneva SE